#1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
8.9
Company: BridgeBio / Pfizer / Alnylam
Drug(s): Attruby (acoramidis) / Vyndamax (tafamidis) / Amvuttra (vutrisiran)
Revenue Potential: $337.5M
Urgency: HIGH — Vyndaqel patent expiring, Attruby launching, all three companies racing to diagnose patients
Relationships: BridgeBio: WarmPfizer: Warm
Entry Strategy: Three-way competitive market creates urgency for all players to identify patients first. Pfizer (cold), BridgeBio (cold), Alnylam (cold). Target commercial leads at each.
Key Events & Sources
- Pfizer withdrew EU patent for Vyndaqel (Feb 2026)
- BridgeBio Attruby FDA approved (Nov 2024)
- Alnylam Amvuttra approved for ATTR-CM (2024)
- Vyndaqel US patent expires ~Dec 2026
#2 Geographic Atrophy (GA) secondary to AMD
7.0
Company: Apellis / Iveric Bio (Astellas)
Drug(s): Syfovre (pegcetacoplan) / Izervay (avacincaptad pegol)
Revenue Potential: $225.0M
Urgency: MEDIUM-HIGH — New class, commercial ramp ongoing, undiagnosed pool massive
Relationships:
Entry Strategy: New treatment category — both companies building commercial infrastructure. Early-stage identification of GA patients is critical for uptake.
Key Events & Sources
- Syfovre approved Feb 2023, Izervay approved Aug 2023
- Both companies scaling commercial teams 2025-2026
All data points sourced. Click links for verification.
Score = Market Size (35%) × Urgency (25%) × Accessibility (20%) × Strategic Fit (20%)